K
Kevin Staveley-O'Carroll
Researcher at Johns Hopkins University
Publications - 22
Citations - 2786
Kevin Staveley-O'Carroll is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 8 publications receiving 2660 citations. Previous affiliations of Kevin Staveley-O'Carroll include Johns Hopkins University School of Medicine.
Papers
More filters
Journal Article
Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentation of Tumor Antigen
Ken Yu Lin,Frank G. Guarnieri,Kevin Staveley-O'Carroll,Hyam I. Levitsky,J. Thomas August,Drew M. Pardoll,Tzyy Choou Wu +6 more
TL;DR: It is demonstrated that modifications that reroute a cytosolic tumor antigen to the endosomal/lysosomal compartment can profoundly improve the in vivo therapeutic potency of recombinant vaccines.
Journal ArticleDOI
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
Kevin Staveley-O'Carroll,Eduardo M. Sotomayor,Jami Montgomery,Ivan Borrello,Leon Hwang,Steve Fein,Drew M. Pardoll,Hyam I. Levitsky +7 more
TL;DR: The development of antigen-specific T cell anergy is an early event in the tumor-bearing host, and it suggests that tolerance to tumor antigens may impose a significant barrier to therapeutic vaccination.
Journal ArticleDOI
Engineering an intracellular pathway for major histocompatibility complex class ii presentation of antigens
Tzyy Choou Wu,Frank G. Guarnieri,Kevin Staveley-O'Carroll,Raphael P. Viscidi,Hyam I. Levitsky,Lora Hedrick,Kathleen R. Cho,J. T. August,Drew M. Pardoll +8 more
TL;DR: In vivo immunization experiments in mice demonstrated that vaccinia containing the chimeric E7/LAMP-1 gene generated greater E7-specific lymphoproliferative activity, antibody titers, and cytotoxic T-lymphocyte activities than vacciniacontaining the wild-type HPV-16 E7 gene.
Journal ArticleDOI
Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.
Eduardo M. Sotomayor,Ivan Borrello,Frederique Rattis,Alex G. Cuenca,Jacob Abrams,Kevin Staveley-O'Carroll,Hyam I. Levitsky +6 more
TL;DR: It is unambiguously demonstrated that in the absence of host APC presentation, tumor-specific T cells remained functional, even in the setting of antigen expressed by B-cell lymphomas residing in secondary lymphoid tissues.
Journal Article
Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity
Hyam I. Levitsky,Jami Montgomery,Mojgan Ahmadzadeh,Kevin Staveley-O'Carroll,Frank G. Guarnieri,Dan L. Longo,Larry W. Kwak +6 more
TL;DR: This is the first demonstration that T cell responses specific for a native tumor Ag are generated by GM-CSF-transduced tumor cell-based vaccination, suggesting that B cell lymphoma may be a suitable disease for genetically modified tumor vaccine strategies.